Table 2.
Species and antimicrobial susceptibility profile of mycobacterial isolates
| Antimicrobial | Susceptible mycobacterial isolates (%) | ||||||
|---|---|---|---|---|---|---|---|
| Overall susceptibility (%) | M. abscessus (n = 5) | M. arupense (n = 1) | M. avium intracellulare (n = 12) | M. chelonae (n = 17) | M. chelonae/ abscessus (n = 2) | M. immunogenum (n = 4) | |
| Amikacin | 27·6 | 20 | 100 | n.d. | 11·8 | 50 | 100 |
| Cefoxitin | 0 | 0 | n.d. | n.d. | n.d. | n.d. | 0 |
| Ciprofloxacin | 6·9 | 0 | 100 | n.d. | 0 | 0 | 25 |
| Clarithromycin | 95·1 | 80 | 100 | 100 | 100 | 50 | 100 |
| Ethambutol | 100 | n.d. | 100 | n.d. | n.d. | n.d. | n.d. |
| Imipenem | 0 | 0 | n.d. | n.d. | 0 | 0 | 0 |
| Linezolid | 36·6 | 20 | 100 | 16·7 | 58·8 | 50 | 0 |
| Moxifloxacin | 7·3 | 0 | 100 | 16·7 | 0 | 0 | 0 |
| Rifampin | 100 | n.d. | 100 | n.d. | n.d. | n.d. | n.d. |
| Rifabutin | 100 | n.d. | 100 | n.d. | n.d. | n.d. | n.d. |
| Tobramycin | 88·2 | n.d. | n.d. | n.d. | 88·2 | 50 | n.d. |
| Trimethroprim-sulfamethoxazole | 3·4 | 0 | 100 | n.d. | 0 | 0 | 0 |
n.d., Not done or not interpretable; non-susceptible: doxycycline, minocycline.